Read More

Aileron Therapeutics Presents Data At AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity As Radioprotective Agent In Preclinical Models Of Acute Radiation-Induced Toxicity

Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new preclinical data at the AACR-NCI-EORTC

ALRN